Posttranscriptional changes of serum albumin: Clinical and prognostic significance in hospitalized patients with cirrhosis

Hepatology

Volumn 60, Issue 6, 2014, Pages 1851-1860

  Domenicali, Marco ^a,b   Baldassarre, Maurizio ^a,b   Giannone, Ferdinando A ^a,b   Naldi, Marina ^a   Mastroroberto, Marianna ^a   Biselli, Maurizio ^a   Laggetta, Maristella ^a,b   Patrono, Daniela ^b   Bertucci, Carlo ^a   Bernardi, Mauro ^a,b   Caraceni, Paolo ^a,b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMINOID; ISOPROTEIN;

ADULT; AGED; CASE CONTROL STUDY; COMPLICATION; DIABETES MELLITUS; EPIDEMIOLOGY; FEMALE; HUMAN; ITALY; LIVER CIRRHOSIS; MALE; METABOLISM; MIDDLE AGED; MORTALITY; NORMAL HUMAN; PROTEIN PROCESSING; RNA PROCESSING;

ADULT; AGED; ALBUMINS; CASE-CONTROL STUDIES; DIABETES COMPLICATIONS; FEMALE; HEALTHY VOLUNTEERS; HUMANS; ITALY; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROTEIN ISOFORMS; PROTEIN MODIFICATION, TRANSLATIONAL; RNA PROCESSING, POST-TRANSCRIPTIONAL;

EID: 84911940404     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27322     Document Type: Article

References (33)

1. Anraku M, Chuang VTG, Maruyama T, Otagiri M. Redox properties of serum albumin. Biochim Biophys Acta 2013;1830:5465-5472.
2. Garcia-Martinez R, Caraceni P, Bernardi M, Gines P, Arroyo V, Jalan R. Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications. Hepatology 2013;:1836-1846.
3. Evans T. Review article: albumin as a drug-biological effects of albumin unrelated to oncotic pressure. Aliment Pharmacol Ther 2002;16:6-11.
4. Fanali G, Di Masi A, Trezza V, Marino M, Fasano M, Ascenzi P. Human serum albumin: from bench to bedside. Mol Aspects Med 2012;33:209-290.
5. Peters T. All About Albumin: Biochemistry, Genetics, and Medical Applications. San Diego, CA: Academic; 1996.
6. Bar-Or D, Curtis G, Rao N, Bampos N, Lau E. Characterization of the Co(2+) and Ni(2+) binding amino-acid residues of the N-terminus of human albumin. An insight into the mechanism of a new assay for myocardial ischemia. Eur J Biochem 2001;268:42-47.
7. Carballal S, Alvarez B, Turell L, Botti H, Freeman BA, Radi R. Sulfenic acid in human serum albumin. Amino Acids 2007;32:543-551.
8. Rondeau P, Bourdon E. The glycation of albumin: structural and functional impacts. Biochimie 2011;93:645-658.
9. Chan B, Dodsworth N, Woodrow J, Tucker A, Harris R. Site-specific N-terminal auto-degradation of human serum albumin. Eur J Biochem 1995;227:524-528.
10. Kawakami A, Kubota K, Yamada N, Tagami U, Takehana K, Sonaka I, et al. Identification and characterization of oxidized human serum albumin. A slight structural change impairs its ligand-binding and antioxidant functions. FEBS J 2006;273:3346-3357.
11. Quinlan GJ, Margarson MP, Mumby S, Evans TW, Gutteridge JM. Administration of albumin to patients with sepsis syndrome: a possible beneficial role in plasma thiol repletion. Clin Sci (Lond) 1998;95:459-465.
12. Gentile S, Loguercio C, Marmo R, Carbone L, Del Vecchio Blanco C. Incidence of altered glucose tolerance in liver cirrhosis. Diabetes Res Clin Pract 1993;22:37-44.
13. Iberg N, Flückiger R. Nonenzymatic glycosylation of albumin in vivo. Identification of multiple glycosylated sites. J Biol Chem 1986;261:13542-13545.
14. Watanabe A, Matsuzaki S, Moriwaki H, Suzuki K, Nishiguchi S. Problems in serum albumin measurement and clinical significance of albumin microheterogeneity in cirrhotics. Nutrition 2004;20:351-357.
15. Oettl K, Stadlbauer V, Petter F, Greilberger J, Putz-Bankuti C, Hallström S, et al. Oxidative damage of albumin in advanced liver disease. Biochim Biophys Acta 2008;1782:469-473.
16. Stauber RE, Spindelboeck W, Haas J, Putz-Bankuti C, Stadlbauer V, Lackner C, et al. Human nonmercaptalbumin-2: a novel prognostic marker in chronic liver failure. Ther Apher Dial 2014;18:74-78.
17. Oettl K, Birner-Gruenberger R, Spindelboeck W, Stueger HP, Dorn L, Stadlbauer V, et al. Oxidative albumin damage in chronic liver failure: relation to albumin binding capacity, liver dysfunction and survival. J Hepatol 2013;59:978-983.
18. Jalan R, Schnurr K, Mookerjee RP, Sen S, Cheshire L, Hodges S, et al. Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality. Hepatology 2009;50:555-564.
19. Naldi M, Giannone FA, Baldassarre M, Domenicali M, Caraceni P, Bernardi M, Bertucci C. A fast and validated mass spectrometry method for the evaluation of human serum albumin structural modifications in the clinical field. Eur J Mass Spectrom (Chichester, Eng) 2013;19:491-496.
20. Bar-Or D, Bar-Or R, Rael LT, Gardner DK, Slone DS, Craun ML. Heterogeneity and oxidation status of commercial human albumin preparations in clinical use. Crit Care Med 2005;33:1638-1641.
21. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-699.
22. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464-470.
23. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-649.
24. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002;35:716-721.
25. American Diabetes Association. Standards of medical care in diabetes-2012. Diabetes Care 2012;35(Suppl. 1):S11-S63.
26. Kleinova M, Belgacem O, Pock K, Rizzi A, Buchacher A, Allmaier G. Characterization of cysteinylation of pharmaceutical-grade human serum albumin by electrospray ionization mass spectrometry and low-energy collision-induced dissociation tandem mass spectrometry. Rapid Commun Mass Spectrom 2005;19:2965-2973.
27. Colombo G, Clerici M, Giustarini D, Rossi R, Milzani A, Dalle-Donne I. Redox albuminomics: oxidized albumin in human diseases. Antioxid Redox Signal 2012;17:1515-1527.
28. Carballal S, Radi R, Kirk MC, Barnes S, Freeman BA, Alvarez B. Sulfenic acid formation in human serum albumin by hydrogen peroxide and peroxynitrite. Biochemistry 2003;42:9906-9914.
29. Shaklai N, Garlick RL, Bunn HF. Nonenzymatic glycosylation of human serum albumin alters its conformation and function. J Biol Chem 1984;259:3812-3817.
30. Sen S, Williams R, Jalan R. The pathophysiological basis of acute-on-chronic liver failure. Liver 2002;22(Suppl. 2):5-13.
31. Girón-González JA, Martínez-Sierra C, Rodriguez-Ramos C, Macías MA, Rendón P, Díaz F, et al. Implication of inflammation-related cytokines in the natural history of liver cirrhosis. Liver Int 2004;24:437-445.
32. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006;44:217-231.
33. Jalan R, Bernardi M. Effective albumin concentration and cirrhosis mortality: from concept to reality. J Hepatol 2013;59:918-920.